Comparison of HPV genotyping and methylated ZNF582 as triage for women with equivocal liquid-based cytology results

Clinical Epigenetics

Volumn 7, Issue 1, 2015, Pages

  Liou, Yu Ligh ^a,b,d   Zhang, Yu ^a   Liu, Yingzi ^a,b   Cao, Lanqin ^a   Qin, Chong Zhen ^a   Zhang, Tao Lan ^a   Chang, Chi Feng ^d   Wang, Huei Jen ^d   Lin, Shu Yi ^e   Chu, Tang Yuan ^c,f   Zhang, Yi ^a   Zhou, Hong Hao ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d ISTAT BIOMEDICAL CO LTD   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

^f TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Biomarker; Cervical cancer; DNA methylation; HPV 16 18; HPV HR; ZNF582

Indexed keywords

UNCLASSIFIED DRUG; VIRUS DNA; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 582;

ARTICLE; CANCER GRADING; CANCER RISK; CASE CONTROL STUDY; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; DNA METHYLATION; EMERGENCY HEALTH SERVICE; FEMALE; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; INTERMETHOD COMPARISON; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROTEIN METHYLATION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; ZNF582 GENE;

HUMAN PAPILLOMAVIRUS;

EID: 84939519811     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-015-0084-2     Document Type: Article

References (36)

1. Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev. 2011;12:1149–53.
2. Zhao P, Dai M, Chen W, Li N. Cancer trends in China. Jpn J Clin Oncol. 2010;40:281–5.
3. Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer. 2012;130:641–52.
4. Pan QJ, Hu SY, Guo HQ, Zhang WH, Zhang X, Chen W, et al. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China. Gynecol Oncol. 2014;133:172–9.
5. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727–35.
6. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, et al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2013;132:101–8.
7. Barreth D, Schepansky A, Capstick V, Johnson G, Steed H, Faught W. Atypical squamous cells - cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a result not to be ignored. J Obstet Gynaecol Can. 2006;28:1095–8.
8. Saavedra KP, Brebi PM, Roa JC. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics. 2012;4:13.
9. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871–6.
10. Apgar BS, Brotzman G. Management of cervical cytologic abnormalities. Am Fam Physician. 2004;70:1905–16.
11. Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, et al. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer. 2010;116:4266–74.
12. Lin CJ, Lai HC, Wang KH, Hsiung CA, Liu HW, Ding DC, et al. Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results. Am J Obstet Gynecol. 2011;204:21e1–7.
13. Sobti RC, Singh N, Hussain S, Suri V, Nijhawan R, Bharti AC, et al. Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis. Cell Oncol (Dordr). 2011;34:533–43.
14. Farkas SA, Milutin-Gasperov N, Grce M, Nilsson TK. Genome-wide DNA methylation assay reveals novel candidate biomarker genes in cervical cancer. Epigenetics. 2013;8:1213–25.
15. Lendvai A, Johannes F, Grimm C, Eijsink JJ, Wardenaar R, Volders HH, et al. Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade intraepithelial neoplasia. Epigenetics. 2012;7:1268–78.
16. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112:293–9.
17. van der Meide WF, Snellenberg S, Meijer CJ, Baalbergen A, Helmerhorst TJ, van der Sluis WB, et al. Promoter methylation analysis of WNT/β-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix. Gynecol Oncol. 2011;123:116–22.
18. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008;123:161–7.
19. Eijsink JJ, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer. 2012;130:1861–9.
20. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi) genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14:395–405.
21. Huang RL, Chang CC, Su PH, Chen YC, Liao YP, Wang HC, et al. Methylomic analysis identifies frequent DNA methylation of zinc finger protein 582 (ZNF582) in cervical neoplasms. PLoS ONE. 2012;7:e41060.
22. Lin H, Chen TC, Chang TC, Cheng YM, Chen CH, Chu TY, et al. Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions - a Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecol Oncol. 2014;135:64–8.
23. Chang CC, Huang RL, Wang HC, Liao YP, Yu MH, Lai HC. High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma. Int J Gynecol Cancer. 2014;24:201–9.
24. Ngan HY, Garland SM, Bhatla N, Pagliusi SR, Chan KK, Cheung AN, et al. Asia Oceania guidelines for the implementation of programs for cervical cancer prevention and control. J Cancer Epidemiol. 2011;2011, e794861.
25. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.
26. Lin H, Moh JS, Ou YC, Shen SY, Tsai YM, ChangChien CC, et al. A simple method for the detection and genotyping of high-risk human papillomavirus using seminested polymerase chain reaction and reverse hybridization. Gynecol Oncol. 2005;96:84–91.
27. Pan QJ, Hu SY, Zhang X, Ci PW, Zhang WH, Guo HQ, et al. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China. Cancer Cytopathol. 2013;121:473–82.
28. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003;127:946–9.
29. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383–92.
30. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516–42.
31. Li H, Zhang J, Chen Z, Zhou B, Tan Y. Prevalence of human papillomavirus genotypes among women in Hunan province, China. Eur J Obstet Gynecol Reprod Biol. 2013;170:202–5.
32. Quek SC, Lim BK, Domingo E, Soon R, Park JS, Vu TN, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. Int J Gynecol Cancer. 2013;23:148–56.
33. Chen CA, Liu CY, Chou HH, Chou CY, Ho CM, Twu NF, et al. The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: a Taiwan cooperative oncologic group study. Int J Gynecol Cancer. 2006;16:1801–8.
34. De Strooper LM, Hesselink AT, Berkhof J, Meijer CJ, Snijders PJ, Steenbergen RD, et al. Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women. Cancer Epidemiol Biomarkers Prev. 2014;23:1933–7.
35. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91:252–8.
36. McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG. 2004;111:1437–43.